Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Relay Therapeutics (Nasdaq: RLAY) announced that management will participate in fireside chats at three investor conferences in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relay Therapeutics (Nasdaq: RLAY) announced that management will participate in fireside chats at three investor conferences in November 2026.
The schedule includes Guggenheim on November 10 at 4:30 p.m. ET, UBS on November 17 at 3:00 a.m. ET, and Jefferies on November 18 at 10:30 a.m. ET. Live webcasts will be accessible through the company’s website, with archived replays available for up to 30 days following each event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in three upcoming fireside chats in November:
- Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 4:30 p.m. ET
- UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 8:00 a.m. GMT / 3:00 a.m. ET
- Jefferies Global Healthcare Conference on Wednesday, November 18, 2026 at 3:30 p.m. GMT / 10:30 a.m. ET
The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations. An archived replay of the webcast will be available for up to 30 days following the event.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.
Contact:
Mitch Maisel
mmaisel@relaytx.com
Media:
Katie Engleman
1AB
919-333-7722
katie@1abmedia.com
